What You Should Know:
– Coming out of stealth, Notable Labs, a pioneer and developer of predictive precision medicines, is acquiring worldwide development and commercial rights to volasertib, a PLK-1 inhibitor in acute myeloid leukemia (AML) from Oncoheroes.
– Notable will leverage its high-fidelity Predictive Precision Medicines Platform to identify and select volasertib-responsive patients prior to their treatment and fast-track volasertib’s clinical development in this patient population.
– Notable’s proprietary platform was built upon deep expertise across therapeutics, diagnostics, software, engineering, machine learning and automation. It quickly determines the response profile of individual patients prior to their cancer treatment, allowing for selective enrollment of predicted clinical responders into clinical trials.
Under terms of the agreement, Notable will have exclusive rights to develop and commercialize volasertib in leukemias, lymphomas and other adult cancer indications. Oncoheroes will retain the license for the development and commercialization of volasertib in other pediatric indications. Financial terms of this deal are not disclosed.
Predictive Precision Medicines
Notable represents a new way to develop therapies – with data and analytics behind it – and the company’s data is supported by a recent Stanford study showing a 92% accuracy in predicting patient response. Traditional precision medicine uses biomarkers and genetic screening to improve development success. It works but in the big picture, it has decreased failure only moderately – from 96.6% to 95%. Notable’s platform was built upon the team’s deep expertise in therapeutics, diagnostics, software, engineering, machine learning and automation.
“Volasertib represents an exciting milestone towards fulfilling Notable’s mission to deliver life-changing therapies precisely to those who will benefit, and leads the way in a new era of predictive precision medicine,” said Thomas Bock, M.D., Chief Executive Officer of Notable. “We targeted and licensed volasertib because of its compelling performance on our Predictive Precision Medicine Platform and as an important addition to our growing clinical pipeline. We plan to fast-track volasertib’s development with phase 2/3 clinical trials in AML and other cancers, selectively enrolling patients who are predicted to respond.”